Creso Pharma’s acquisition of Halucenex Life Sciences marks the first fully-owned psychedelic medicines company on the ASX
* TV
15 minutes ago|* TV
Medical marijuana companyCreso Pharma (ASX:CPH)has just entered the emerging $100 billion global market for psychedelic medicine with acquisition of Canada-based Halucenex Life Sciences.
The agreement provides Creso Pharma with entry into the emerging global market for psychedelics medicines – estimated to be worth up to US$100Bn.
The acquisition marks the first fully-owned psychedelic medicines company on the ASX.
Halucenex is a Psychedelic-Assisted Psychotherapy (PAP) company. As a result of the acquisition, it will benefit from significant synergies including Creso Pharma’s experienced pharmaceutical product development team, industry leading advisers, a comprehensive global distribution network and a top-tier premium cannabis cultivation facility.
Watch the interview below with Creso strategic advisor, Bruce Linton, and founder of Canopy Growth (NYSE:CGC), the world’s largest cannabis company share his thoughts on the acquisition.
This article was developed in collaboration with Creso Pharma, a * advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
- Forums
- ASX - By Stock
- Ann: Creso to Acquire Psychedelics Company, Halucenex
Creso Pharma’s acquisition of Halucenex Life Sciences marks the...
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online